CCR5 cell surface density and HIV-1 envelope sequences govern antiretroviral potency of CCR5 antagonists

被引：0
|
作者：
Miller, MD
Lineberger, JE
Dornadula, G
Danzeisen, RC
Blau, CR
Danovich, RM
Miller, MA
Finke, PE
Oates, BD
Caldwell, CG
Chen, P
Meurer, LC
Mills, SG
Springer, MS
Petropoulos, CJ
Whitcomb, J
Huang, W
Fransen, S
Simon, AJ
Hazuda, DJ
机构：
[1] Merck Res Labs, Dept Biol Chem, West Point, PA USA
[2] Merck Res Labs, Dept Microbial Vaccine Res, West Point, PA USA
[3] Dept Med Chem, Rahway, NJ USA
[4] Dept Immunol & Rheumatol, Rahway, NJ USA
[5] ViroLog Inc, San Francisco, CA USA
来源：
ANTIVIRAL THERAPY | 2003年 / 8卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
61
引用
收藏
页码：U66 / U67
页数：2
相关论文
共 50 条
  • [11] CCR5 inhibitors in HIV-1 therapy
    Dorr, Patrick
    Perros, Manos
    EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (11) : 1345 - 1361
  • [12] Spiropiperidine CCR5 antagonists
    Rotstein, David M.
    Gabriel, Stephen D.
    Makra, Ferenc
    Filonova, Lubov
    Gleason, Shelley
    Brotherton-Pleiss, Christine
    Setti, Lina Q.
    Trejo-Martin, Alejandra
    Lee, Eun Kyung
    Sankuratri, Surya
    Ji, Changhua
    deRosier, Andre
    Dioszegi, Marianna
    Heilek, Gabrielle
    Jekle, Andreas
    Berry, Pamela
    Weller, Paul
    Mau, Cheng-I
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (18) : 5401 - 5406
  • [13] Resistance to CCR5 antagonists
    Westby, Mike
    CURRENT OPINION IN HIV AND AIDS, 2007, 2 (02) : 137 - 144
  • [14] Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands
    Ketas, Thomas J.
    Kuhmann, Shawn E.
    Palmer, Ashley
    Zurita, Juan
    He, Weijing
    Ahuja, Sunil K.
    Klasse, Per Johan
    Moore, John P.
    VIROLOGY, 2007, 364 (02) : 281 - 290
  • [15] Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection
    Lin, YL
    Mettling, C
    Portales, P
    Reynes, J
    Clot, J
    Corbeau, P
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (24) : 15590 - 15595
  • [16] CCR5 Utilization of Transmitted and Early Founder HIV-1 Envelopes and the Sensitivity to Small CCR5 Inhibitors
    Hu, Q.
    Keele, B.
    Ping, L.
    Grayson, T.
    Sun, C.
    Hahn, B.
    Shattock, R.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2008, 24 : 6 - 6
  • [17] Differential use of CCR5 by HIV-1 clinical isolates resistant to small molecule CCR5 inhibitors
    Henrich, T. J.
    Lewine, N.
    Lee, S-H
    Rao, S.
    Berro, R.
    Greaves, W.
    Gulick, R.
    Tsibris, A.
    Moore, J.
    Kuritzkes, D.
    ANTIVIRAL THERAPY, 2011, 16 : A59 - A59
  • [18] The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density
    Desmetz, Caroline
    Lin, Yea-Lih
    Mettling, Clement
    Portales, Pierre
    Rabesandratana, Herisoa
    Clot, Jacques
    Corbeau, Pierre
    IMMUNOLOGY, 2006, 119 (04) : 551 - 561
  • [19] Choosing CCR5 or Rev siRNA in HIV-1
    Arteaga, HJ
    Hinkula, J
    van Dijk-Härd, I
    Dilber, MS
    Wahren, B
    Christensson, B
    Mohamed, AJ
    Smith, CIE
    NATURE BIOTECHNOLOGY, 2003, 21 (03) : 230 - 231
  • [20] CCR5 antagonists and HIV-1 infection: Bases and consequences of this therapeutic approach
    Psomas, K. C.
    Corbeau, P.
    Reynes, J.
    ANTIBIOTIQUES, 2010, 12 (01): : 27 - 41
12345